G-CSF对淋巴瘤患者18F-FDG生物分布的影响:PET/CT时序安排启示
该回顾性研究纳入74例接受免疫化疗的弥漫大B细胞淋巴瘤患者,分析G-CSF类型及末次注射至中期PET/CT的时间间隔对18F-FDG在骨髓、肝脏、脾脏摄取的影响。结果表明G-CSF类型和间隔时间并非独立影响因素,而化疗结束至检查的时间间隔是骨髓和脾脏高代谢的主要决定因素,建议保持在15天以上。
要点
- 化疗结束至中期PET/CT间隔小于17天者骨髓和脾脏SUVmaxEARL更高。
- G-CSF类型及末次注射至检查间隔非骨髓、肝、脾摄取的独立影响因素。
- 肝脾比值反转可能源于脾脏高代谢,对Deauville评分影响不大。
核心结论
- G-CSF类型及末次注射至中期PET/CT的时间间隔均不独立影响骨髓、肝脏或脾脏摄取。
- 化疗结束至中期PET/CT的时间间隔是骨髓或脾脏高代谢的主要决定因素,应保持在15天以上。
- 肝脾比值反转似乎源于中期PET/CT脾脏高代谢增加,对Deauville评分影响可能性小。
研究设计与样本
- 回顾性纳入74例连续弥漫大B细胞淋巴瘤患者,接受基线和中期检查并接受免疫化疗及多种G-CSF方案。
- 综合评估基线代谢活跃肿瘤体积、影响肝脏摄取因素、G-CSF类型及化疗/G-CSF至中期PET/CT的时间间隔。
主要发现
- 基线与中期PET/CT间骨髓、肝脏、脾脏摄取平均百分比变化分别为32.0±46.9%、16.1±42.8%、10.6±51.1%。
- 肝脏和脾脏百分比变化在使用来格司亭患者中更高,但与基线摄取较低相关,可能非G-CSF本身所致。
- 骨髓和脾脏百分比变化与化疗结束至中期PET/CT间隔负相关:ρ=-0.342(p=0.010)和ρ=-0.529(p<0.0001)。
- 化疗末次注射后间隔<17天者骨髓和脾脏SUVmaxEARL更高。
- 肝脏百分比变化与基线代谢活跃肿瘤体积正相关:ρ=0.243(p=0.039)。
关键数值与推荐
- 基线代谢活跃肿瘤体积≥177 cc者基线肝脏SUVmaxEARL显著更低,肿瘤缩小后中期PET/CT该差异不再存在。
- 化疗结束至中期PET/CT间隔应保持在15天以上。
临床怎么用
- 安排中期PET/CT时,应确保化疗结束至检查间隔超过15天以减少骨髓和脾脏高代谢干扰。
- G-CSF类型及末次注射至检查间隔无需作为调整PET/CT时序的主要依据。
局限性
- 回顾性研究设计。
- 样本量74例。
- 未报告其他潜在混杂因素的控制情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: (1) To perform a comprehensive analysis of the time elapsed between the last G-CSF injection and the PET/CT examination on the biodistribution of 18F-FDG, with emphasis on liver, spleen, and bone marrow uptake, and (2) to investigate whether an inversion of the liver to spleen ratio affects the Deauville scoring. MATERIALS AND METHODS: Retrospectively included were 74 consecutive diffuse large B cell lymphoma (DLBCL) patients referred for baseline and interim examinations and receiving immunochemotherapy with various G-CSF regimens. A comprehensive evaluation considering baseline metabolic active tumour volume (MATV), factors affecting liver uptake, the type of G-CSF, and the time elapsed between chemotherapy/G-CSF and interim PET/CTs was performed. RESULTS: Mean (± SD) percentage variations between baseline and interim PET/CTs (i-PET/CT) for bone marrow (%Variation_BONE), liver (%Variation_LIVER) and spleen (%Variation_SPLEEN) were equal to 32.0 ± 46.9%, 16.1 ± 42.8%, and 10.6 ± 51.1 %, respectively. %Variation_LIVER and %Variation_SPLEEN were higher in patients using lenograstim, but this was linked to lower uptakes at baseline and was therefore likely not due to G-CSF itself. The mean delay between G-CSF injection and i-PET/CT acquisition was not an independent explanatory variable for %Variation_BONE, %Variation_LIVER, and %Variation_SPLEEN. On the contrary, %Variation_BONE and %Variation_SPLEEN were negatively correlated to the time-lapse between the end of chemotherapy and i-PET/CT: ρ = - 0.342 (p = 0.010) and ρ = - 0.529 (p < 0.0001), respectively. Patients with a time-lapse since the last injection of chemotherapy < 17 days displayed higher bone and spleen SUVmaxEARL. %Variation_LIVER was positively correlated to baseline MATV: ρ = 0.243 (p = 0.039). Patients displaying a high baseline MATV ≥ 177 cc had significantly lower liver SUVmaxEARL at baseline. This difference was no longer observed at i-PET/CT, after tumours had shrunk. CONCLUSIONS: Neither the type of G-CSF used nor the time elapsed between its last injection and i-PET/CT examination independently influences bone, hepatic, or splenic uptakes at i-PET/CT. The major determinant for the occurrence of a bone or spleen hypermetabolism on i-PET/CT is the time elapsed between the chemotherapy and the examination, which should be maintained above 15 days. Inversion of the liver to spleen ratio appeared to be due to increased spleen hypermetabolism on i-PET/CT, making unlikely an impact on the Deauville scoring.
引用
- Oliveira M, Lasnon C, Nganoa C, et al. Comprehensive analysis of the influence of G-CSF on the biodistribution of 18F-FDG in lymphoma patients: insights for PET/CT scheduling. EJNMMI Res. 2019. PMID: 31432277. doi:10.1186/s13550-019-0546-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。